Ireland
--:--IST
Recruiting Not applicable

Finding Alternatives to Standard Treatment for Attention-Deficit Hyperactivity Disorder

NCT04532190 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2026-03-01
Last updated
2026-05-14

Condition(s) studied

Attention-Deficit/Hyperactivity Disorder (ADHD)

Investigational drug(s) / intervention(s)

rTMS

rTMS: Repetitive transcranial magnetic stimulation (rTMS)

Study summary

Attention-Deficit/Hyperactivity Disorder (ADHD) is characterized by poor attention, impulsivity, hyperactivity and emotional-motivational dysregulation. Here, we will test if theta burst repetitive transcranial magnetic stimulation (rTMS) can reduce the symptoms of ADHD.

Eligibility

Sex
ALL
Min age
9 Years
Max age
15 Years
Healthy volunteers
No
Inclusion Criteria: 1. Diagnosis of ADHD 2. 9-15 years old 3. IQ greater than 80 4. English fluency (to enable consent/assent) 5. If on medication, must have been on the same type and dosage for at least 3 months. Exclusion Criteria: 1. Diagnosis of mania, psychosis, or bipolar disorder 2. Impediments to TMS or MRI (i.e. metal implants in body) 3. Prior electroconvulsive therapy or vagus nerve stimulation 4. Diagnosis of Autism Spectrum Disorder.

Primary outcome measure(s)

  • TEACH-2 — Baseline to week 5
    Test of everyday attention in children - 2. Direct assessment of attention abilities in children.

Trial sites (1)

FacilityCityRegionStatus
Alberta Children's Hospital Calgary Alberta Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04532190 on ClinicalTrials.gov ↗ ← All trials in Canada